Experimental application of a split-conjugated vaccine against animal brucellosis in small cattle

Veselovskiy, Stepan; Агольцов, В А; Popova, Olga Mikhailovna

doi:10.28983/asj.v0i10.600

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to our experiment, the tested vaccine with immunomodulatory (polypeptide C and fosprenil) also enhances the humoral immune response. Our previous experiment (vaccine tested, and with polyoxidonium immunomodulatory) also showed an increase in humoral immunity in animals [23]. Furthermore, fosprenil is used in conjunction with other vaccines.…”

Section: Discussionmentioning

confidence: 76%

Clinical results of an inactivated anti-brucella vaccine in combination with immunomodulators

et al. 2020

View full text Add to dashboard Cite

Aim: The aim of the study was to obtain a vaccine against animal brucellosis having high immunogenic properties by carrying an evaluation of the effectiveness of split-conjugated animal brucellosis vaccine combined with fosprenil and polypeptide C as a molecular immunomodulatory adjuvant according to the results of serological studies of the blood of animals: Agglutination reaction, complement fixation, and rose Bengal sample. Materials and Methods: Eighteen calves of Holstein Friesians breed, aged 5 months, with a living weight of 100-150 kg, were divided into three groups of six animals each. All animals were healthy and they received a prophylactic vaccination against brucellosis. The dry split-conjugated vaccine against brucellosis in animals was dissolved in saline and for this purpose, 10 ml of saline was poured into the vaccine vial. Then the content was mixed, and afterward 1 ml was used per animal. Fosprenil was used at the rate of 1 kg of animal weight: 100 kg (calf weight) was multiplied by 0.05 (dose/1 kg of animal weight); 5 ml of fosprenil was obtained, which was collected into disposable syringes and intramuscularly sterilely injected into the croup area. Calves in the first group (control) were intramuscularly injected with the vaccine at a dose of 1.0 ml, and fosprenil at a dose of 5.0 ml was administered intramuscularly once to the croup area. Animals from the second group were subcutaneously immunized by the vaccine with polypeptide C at a dose of 1.0 ml. Polypeptide C is a solution that was poured into a vial with a vaccine at a dose of 10.0 ml, the content was mixed, and then calves were injected subcutaneously into the middle third of the neck in 1 ml (10 doses in a vial). Immunization of calves in the third group was carried out with a vaccine, diluted with an isotonic sodium chloride solution of 0.9%, at a dose of 1.0 ml subcutaneously once. At the 14th, 30th, and 90th days after vaccination, a blood sampling was taken for serological tests: Agglutination test, complement fixation test, and rose Bengal test. Results: After conducting serological studies, it was noted that split-conjugated vaccine against animal brucellosis using fosprenil forms antibodies in large titers and they persist for a longer time in the body of animals compared to the other tested vaccine: The first combination with the immunomodulatory polypeptide C and the vaccine only on the physiological solution. Conclusion: The developed complex of split-conjugated vaccine against brucellosis in animals enhances the humoral immune response of the organism against brucellosis and improves the protection of animals against the disease when it is used with the immunomodulatory fosprenil. In the future, we want to expand the use of the resulting complex in the fight against brucellosis on a larger population and to study the change in cellular immunity after the introduction of the resulting complex on an animal organism.

show abstract

Section: Discussionmentioning

confidence: 76%

Clinical results of an inactivated anti-brucella vaccine in combination with immunomodulators

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Российские исследователи провели эксперименты по конструированию и применению инактивированной сплит-конъюгированной вакцины для вакцинации мелкого рогатого скота [39]. В ходе проведённых исследований установлена высокая иммуногенность данной вакцины в отношении коз, что позволит эффективно использовать её в борьбе с бруцеллёзом этого вида животных.…”

Section: обзорыunclassified

The past, present, prospects and problems of improving the specifi c prevention of brucellosis

Korshenko

Щипелева

Кретенчук

et al. 2021

Med. vestn. Ûga Ross.

View full text Add to dashboard Cite

Brucellosis remains the most widespread zoonotic infection in the world. Th e spread of the infection is controlled by animals vaccination because the high morbidity rate of the population is associated with the spread of infection among livestock. Th e research is ongoing on a commercial preparation of an eff ective and safe vaccine for immunization of humans and animals against brucellosis. Th e review is devoted to the prospects and problems of improving the specifi c prevention of brucellosis. Th e authors analyzed scientifi c publications from various databases of electronic libraries, such as PubMed, e-library, CyberLeninka, etc.

show abstract

Experimental application of a split-conjugated vaccine against animal brucellosis in small cattle

Cited by 2 publications

References 2 publications

Clinical results of an inactivated anti-brucella vaccine in combination with immunomodulators

Clinical results of an inactivated anti-brucella vaccine in combination with immunomodulators

The past, present, prospects and problems of improving the specifi c prevention of brucellosis

Contact Info

Product

Resources

About